Comparing Tresiba and Lantus: Insulin Therapy Choices Assessed
News Article: Comparing Tresiba and Lantus for Diabetes Management
Tresiba and Lantus are two long-acting insulins used to improve glycemic control in adults and children with type 1 and type 2 diabetes. Although they share similarities, they differ in several aspects, including duration of action, approved age groups, dosing flexibility, and side effect profiles.
Effectiveness
Both Tresiba (insulin degludec) and Lantus (insulin glargine) are effective for managing blood glucose levels in diabetes patients. Tresiba, with a longer duration of action (over 24 hours, up to 42 hours), provides more stable basal insulin coverage, offering potentially lower hypoglycemia risk compared to Lantus, which lasts about 12–24 hours [1].
Dosage and Age Indications
Tresiba is approved for use in children as young as 1 year old and adults, with once-daily injection. It allows more flexible dosing times; if a dose is missed, it can be taken as soon as remembered as long as there is at least 8 hours between doses [1]. In contrast, Lantus is approved for children aged 6 years and older and adults, also given once daily, but it is recommended to be administered at the same time every day for consistent effect [1].
For type 1 diabetes in children ages 6 years and older, the dose of Tresiba is about one-third to one-half of their total daily insulin dosage, while the dose of Lantus is about one-third of their total daily insulin dosage. For adults, the dose of Tresiba is approximately one-third to one-half of their total daily insulin dosage, while the dose of Lantus is about one-third [1].
Side Effects
Both insulins share common side effects such as hypoglycemia (low blood sugar), injection site reactions, and potential weight gain. Tresiba’s longer action and flexible dosing may help reduce hypoglycemia risk, but individual experiences vary [1][5].
Comparison Table
| Feature | Tresiba (Insulin Degludec) | Lantus (Insulin Glargine) | |------------------------------|--------------------------------|-------------------------------------| | Insulin type | Insulin degludec | Insulin glargine | | Duration of action | >24 hours (up to 42 hours) | 12–24 hours | | Approved age for pediatric use | 1 year and older | 6 years and older | | Dosing frequency | Once daily, flexible timing | Once daily, fixed timing | | Dosing forms | Flex pen, vial and syringe | SoloStar pen, vial and syringe | | Indications | Type 1 & Type 2 diabetes | Type 1 & Type 2 diabetes | | Hypoglycemia risk | Possibly lower due to longer action and flexible dosing[5] | Present, recommend consistent timing for dose[1] | | Use in children | Yes (≥1 year) | Yes (≥6 years) |
In practice, Tresiba offers more dosing flexibility and a longer duration of action, making it potentially better for patients needing flexible schedules or who are prone to hypoglycemia. Lantus is well-established, widely used, but requires more strict dosing time adherence and is limited to children 6 and older.
Both insulins require careful blood glucose monitoring and dose titration individualized to the patient's metabolic needs. The choice between Tresiba and Lantus depends on patient age, lifestyle, dosing preferences, and physician guidance.
Pharmacy patients with diabetes mellitus should understand the endocrine science behind the long-acting insulins Tresiba and Lantus, as both drugs are used to manage diabetes and are among the medical-conditions commonly treated in health-and-wellness stores. The science of diabetes care involves choosing the right insulin, such as Tresiba, which can provide more stable basal insulin coverage due to a duration of action exceeding 24 hours, reducing the risk of chronic-disease complications like hypoglycemia compared to Lantus. Both insulins have their unique dosage and age indications, making it essential for pharmacists to provide patients with accurate information on their use. Lastly, it is crucial to consider the side effects, including hypoglycemia, injection site reactions, and weight gain, while making an informed decision between Tresiba and Lantus for diabetes management.
